Study Spotlight

Study Spotlight

Omega-3 Fatty Acids May Help Reduce CVD Risk Factors in Patients on Mood Stabilizers


In a randomized, double-blind, placebo-controlled, within-subject trial involving 41 adult psychiatric patients who were receiving olanzapine combined with lithium or valproate sodium, supplementation with omega-3 fatty acids (as fish oil, with less than 1 g/d EPA/DHA) for a period of 6 weeks was found to significantly reduce levels of fibrinogen, and levels of Lp(a) did not increase and non-HDL-cholesterol levels did not go beyond their target levels in the group who received omega-3 fatty acids supplementation, as compared to the group that received a placebo. The authors conclude, "This study suggests that use of short-term omega-3 supplementation added to a combined regimen of olanzapine and mood stabilizer may have a small modulating effect on some cardiovascular risk factors. Trials in longer periods of time and with larger number of patients are needed to further evaluate the effects of omega-3 supplements on preventing cardiovascular risk factors.

Visit the journal website. Subscription required to view the full text of the article.

Socialize
Website by Webfitters